The conjugated ISG15 (ISGylation) has pro-tumorigenic activity, while the extracellular free form has anti-tumorigenic activity in breast cancer [84] and is being considered as a tumor-associated antigen for cancer immunotherapy [85]. This evidence concerns the gene ISG15 and breast carcinoma.